Replies to post #183606 on Anavex Life Sciences Corp (AVXL)

[F1ash]

Now all presentations also for PDD and Rett mask the high and low dose with a footnote stating that it is due to complete blinding of the trial.

Btw. did you not make a calculation from mouse doses that clarified why PDD is only 10mg and 20mg?

I’m aware of single, double, and triple blinded trials.

https://www.eupati.eu/clinical-development-and-trials/concept-blinding-clinical-trials/

I’m unaware of what a “completely blinded” trial is though. Does it refer to keeping investors blinded as well. ;-) :-) (kidding)

I wasn’t aware that the footnote about “complete blinding” was also on the Rett and PDD slides. Weird, because watch this...I’m apparently about to “break the blind” on the PDD trial.

“ to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN ANAVEX2-73
D.3.9.2 Current sponsor code ANAVEX2-73
D.3.10 Strength
D.3.10.1 Concentration unit mg milligram(s)
D.3.10.2 Concentration type equal
D.3.10.3 Concentration number 10 “

“INN - Proposed INN ANAVEX2-73
D.3.9.2 Current sponsor code ANAVEX2-73
D.3.10 Strength
D.3.10.1 Concentration unit mg milligram(s)
D.3.10.2 Concentration type equal
D.3.10.3 Concentration number 20 “

https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004335-36/ES

Oops?


I did do the PDD preclinical dosing calculation (unqualified though I may be)

10 and 20 were well above the needed dose from my amateur calculation for PDD.

Perhaps a brave soul might ask for an explanation at the shareholders meeting? Probably not, I would guess. Too uncomfortable I would imagine.